Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Centre for Addiction and Mental Health
- Principal investigator
- Muhammad Ishrat Husain, MBBS, MD
- Start date
- 2025-04-01
- End date
- 2027-12-01
- Registry ID
- NCT06518720
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.